The Exchange has sought clarification from Syngene International Limited with respect to recent news item captioned Syngene expands Biologics facility with new ADC bioconjugation capability. The response from the Company is attached.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Syngene International to clarify a recent news report about the company expanding its Biologics facility to include new Antibody-Drug Conjugate (ADC) bioconjugation capability. The company has submitted its response to the exchange. This type of clarification is typically sought when there is material news circulating about a listed company, to ensure proper disclosure. ADC bioconjugation is a specialised capability used in developing targeted cancer therapies.
Routine clarification on a positive business development; investors should review the company's attached response for details on the facility expansion, which could support future revenue growth in the high-demand biologics segment.